Summit Therapeutics (SMMT) Q3 2025 earnings summary

Executive summary

• Ivonescimab plus chemotherapy demonstrated significant progression-free survival (PFS) benefit and higher response rates over tislelizumab plus chemotherapy in advanced squamous non-small cell lung cancer (NSCLC), with a manageable safety profile and positive trends in overall survival (OS); these results support a planned Biologics License Application (BLA) submission in Q4 2025.

• The phase III clinical program has expanded to include global studies in colorectal cancer (CRC) and other solid tumors, totaling 14 planned or ongoing phase III trials, with collaborations at leading cancer centers and with Revolution Medicines for RAS-mutant tumors.

• Tumor response rates and duration of response were higher and more durable in the ivonescimab arm, with subgroup analyses showing PFS benefit across all key subgroups.

• Ivonescimab is approved in China for two NSCLC indications; global development and regulatory submissions are ongoing.

• Expanded licensing agreement with Akeso covers additional territories, with milestone and royalty obligations.

Financial highlights

• Ended Q3 2025 with $238.6 million in cash and short-term investments, down from $412.3 million at year-end 2024.

• GAAP operating expenses for Q3 2025 were $234.2 million, up from $58.4 million year-over-year, mainly due to a $111.4 million increase in stock-based compensation.

• Non-GAAP operating expenses for Q3 2025 were $103.4 million, up from $39.0 million year-over-year, reflecting clinical study expansion.

• Net loss for Q3 2025 was $231.8 million ($0.31/share), with an accumulated deficit of $2.08 billion.

• Stock-based compensation expense surged to $130.8 million for Q3 2025 due to modifications to performance-based options.

Outlook and guidance

• BLA submission for ivonescimab in NSCLC planned for Q4 2025; FDA approval contingent on demonstrating statistically significant OS benefit.

• HARMONi-3 squamous cohort enrollment expected to complete in H1 2026, with PFS analysis in H2 2026; non-squamous cohort to complete in H2 2026, with PFS analysis in H1 2027.

• HARMONi-GI3 global phase III in CRC to begin U.S. site activation by year-end, targeting 600 patients; further trial details expected in Q1 2026.

• Clinical trials with Revolution Medicines for RAS-mutant tumors to begin in early 2026.

• Expects continued operating losses and significant cash outflows; current cash is insufficient to fund operations for the next 12 months, requiring additional capital.